Clinical Trials
4 trialsNCT04125693 2022-04-01
Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety
Bayer
Phase 2 Completed
NCT01976741 2021-05-06
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)
Bayer
Phase 1 Completed
NCT03788603 2021-03-29
Rogaratinib (BAY1163877) in Chinese Patients
Bayer
Phase 1 Completed
NCT02592785 2018-04-18
Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors
Bayer
Phase 1 Completed